Incobotulinum Toxin A for Sialorrhea in Parkinson's Disease (PD)/Parkinsonism and Amyotrophic Lateral Sclerosis (ALS)
Status:
Withdrawn
Trial end date:
2013-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and efficacy of Incobotulinum Toxin A
(Xeomin®) injections into the parotid and submandibular glands in patients with Parkinson's
Disease/Parkinsonism and Amyotrophic Lateral Sclerosis (ALS) with troublesome sialorrhea.